Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: HEXAMER THERAPEUTICS INC.
Awarding agency: Department of Defense / Defense Health Agency
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2023-09-29 to 2025-11-28
Current total value of award: $3928061.02
Description: PEPTIDE BASED, SELF-ASSEMBLING, MOLECULAR CARRIER (SCAFFOLD) VACCINE PLATFORM IDEAL FOR DEPLOYMENT DURING AN INFECTIOUS DISEASE PANDEMIC BY OFFERING MANY ADVANTAGES.